Metex

Methotrexate, the active ingredient in Metex, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for injection use. It is employed to modulate immune activity and inhibit rapid cell proliferation in a range of autoimmune and oncologic conditions.

GNH USA supplies Metex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate acts on diseases driven by abnormal immune activation or uncontrolled cell growth. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with leukemic cell replication. - Non‑Hodgkin lymphoma: suppresses malignant lymphoid proliferation. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mild elevation of liver enzymes.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or severe pneumonitis. - Life‑threatening infections due to bone‑marrow suppression.

Methotrexate requires careful monitoring and specific safety measures. - Liver monitoring: perform regular liver function tests to detect hepatotoxicity. - Hematologic monitoring: check complete blood counts to identify cytopenias. - Pregnancy avoidance: contraindicated in pregnancy (Category X) and requires effective contraception. - Renal assessment: evaluate kidney function before and during therapy. - Dose adjustment in elderly: consider lower starting doses for older patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors: may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: enhances risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or mycophenolate: additive immunosuppression. - Live vaccines: risk of infection due to immunosuppression.